{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T14:24:27Z","timestamp":1783347867889,"version":"3.54.6"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T00:00:00Z","timestamp":1780099200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100011542","name":"Center for Clinical and Translational Science, Mayo Clinic","doi-asserted-by":"publisher","award":["92541640\u20132020\/Mayo Clinic"],"award-info":[{"award-number":["92541640\u20132020\/Mayo Clinic"]}],"id":[{"id":"10.13039\/100011542","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009730","name":"Stand Up To Cancer","doi-asserted-by":"publisher","award":["SU2C-AACR-CT1017"],"award-info":[{"award-number":["SU2C-AACR-CT1017"]}],"id":[{"id":"10.13039\/100009730","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1245\/s10434-026-19899-1","type":"journal-article","created":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T16:13:07Z","timestamp":1780157587000},"page":"7471-7476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma: Results From the Prospective NeoACTIVATE Arm C (NCT03554083) Substudy"],"prefix":"10.1245","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4277-8692","authenticated-orcid":false,"given":"Tina J.","family":"Hieken","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Flotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Zahrieh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey E.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mara A.","family":"Piltin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kendall K.","family":"Tasche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garth D.","family":"Nelson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie A.","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James W.","family":"Jakub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip","family":"Pirgousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir S.","family":"Khariwala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Tuttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew S.","family":"Block","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,30]]},"reference":[{"key":"19899_CR1","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"SP Patel","year":"2023","unstructured":"Patel SP, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. N Engl J Med. 2023;388:813\u201323.","journal-title":"N Engl J Med."},{"key":"19899_CR2","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1056\/NEJMoa2402604","volume":"391","author":"CU Blank","year":"2024","unstructured":"Blank CU, Lucas MW, Scolyer RA, et al. Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma. N Engl J Med. 2024;391:1696\u2013708.","journal-title":"N Engl J Med."},{"key":"19899_CR3","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1016\/j.annonc.2024.08.2282","volume":"35","author":"GV Long","year":"2024","unstructured":"Long GV, Blank CU, Amaria RN, et al. Long-term survival with neoadjuvant therapy in melanoma: updated pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Ann Oncol. 2024;35:1232\u20131232.","journal-title":"Ann Oncol."},{"key":"19899_CR4","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1093\/annonc\/mdy226","volume":"29","author":"MT Tetzlaff","year":"2018","unstructured":"Tetzlaff MT, Messina JL, Stein JE, et al. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. Ann Oncol. 2018;29:1861\u20138.","journal-title":"Ann Oncol."},{"key":"19899_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_390614","volume":"43","author":"TJ Hieken","year":"2023","unstructured":"Hieken TJ, Kreidieh F, Aedo-Lopez V, Block MS, McArthur GA, Amaria RN. Neoadjuvant immunotherapy in melanoma: the paradigm shift. Am Soc Clin Oncol Educ Book. 2023;43:e390614.","journal-title":"Am Soc Clin Oncol Educ Book."},{"key":"19899_CR6","first-page":"472","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth-edition cancer staging manual. CA Cancer J Clin. 2017;67:472\u201392.","journal-title":"CA Cancer J Clin."},{"key":"19899_CR7","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1056\/NEJMoa2202170","volume":"386","author":"PM Forde","year":"2022","unstructured":"Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386:1973\u201385.","journal-title":"N Engl J Med."},{"key":"19899_CR8","doi-asserted-by":"publisher","first-page":"2297","DOI":"10.1056\/NEJMoa2404512","volume":"392","author":"A Cercek","year":"2025","unstructured":"Cercek A, Foote MB, Rousseau B, et al. Nonoperative management of mismatch repair-deficient tumors. N Engl J Med. 2025;392:2297\u2013308.","journal-title":"N Engl J Med."},{"key":"19899_CR9","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1001\/jamaoto.2025.1707","volume":"151","author":"AE Moroco","year":"2025","unstructured":"Moroco AE, Nunes K, Alnemri A, et al. Pathologic treatment effect and survival in HPV-negative HNSCC following neoadjuvant nivolumab. JAMA Otolaryngol Head Neck Surg. 2025;151:1127\u201336.","journal-title":"JAMA Otolaryngol Head Neck Surg."},{"key":"19899_CR10","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1056\/NEJMoa1910549","volume":"382","author":"P Schmid","year":"2020","unstructured":"Schmid P, Cortes J, Pusztai L, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810\u201321.","journal-title":"N Engl J Med."},{"key":"19899_CR11","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1038\/s41467-024-45798-8","volume":"15","author":"TJ Hieken","year":"2024","unstructured":"Hieken TJ, Nelson GD, Flotte TJ, et al. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for high-risk operable stage III melanoma: the phase II NeoACTIVATE trial. Nat Commun. 2024;15:1430.","journal-title":"Nat Commun."},{"issue":"4","key":"19899_CR12","doi-asserted-by":"publisher","first-page":"e011706","DOI":"10.1136\/jitc-2025-011706","volume":"13","author":"MS Block","year":"2025","unstructured":"Block MS, Nelson GD, Chen J, et al. Neoadjuvant cobimetinib and atezolizumab with or without vemurafenib for stage III melanoma: outcomes and the impact of the microbiome from the NeoACTIVATE trial. J Immunother Cancer. 2025;13(4):e011706.","journal-title":"J Immunother Cancer."},{"key":"19899_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115688","volume":"227","author":"TJ Hieken","year":"2025","unstructured":"Hieken TJ, Zahrieh D, Flotte TJ, et al. NeoACTIVATE arm C: phase II trial of neoadjuvant atezolizumab and tiragolumab for high-risk operable stage III melanoma. Eur J Cancer. 2025;227:115688.","journal-title":"Eur J Cancer."},{"key":"19899_CR14","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","volume":"28","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Menzies AM, van Akkooi ACJ, et al. Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial. Nat Med. 2022;28:1178\u201388.","journal-title":"Nat Med."},{"issue":"157","key":"19899_CR15","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1001\/jamasurg.2021.7554","volume":"1","author":"ILM Reijers","year":"2022","unstructured":"Reijers ILM, Rawson RV, Colebatch AJ, Rozeman EA, Menzies AM, van Akkooi ACJ, et al. Representativeness of the index lymph node for total nodal basin in pathologic response assessment after neoadjuvant checkpoint inhibitor therapy in patients with stage III melanoma. JAMA Surg. 2022;1(157):335\u201342.","journal-title":"JAMA Surg."},{"key":"19899_CR16","unstructured":"Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node (OMIT). Retrieved 4 January 2026 at https:\/\/www.clinicaltrials.gov\/study\/NCT06754904."},{"key":"19899_CR17","unstructured":"The Multicentre Selective Lymphadenectomy Trial-3 (MSLT-3). Retrieved 4 January 2026 at https:\/\/www.clinicaltrials.gov\/study\/NCT07049276?cond=melanoma&term=MSLT-3&rank=1."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19899-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-026-19899-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-026-19899-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T13:36:58Z","timestamp":1783345018000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-026-19899-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,30]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["19899"],"URL":"https:\/\/doi.org\/10.1245\/s10434-026-19899-1","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,30]]},"assertion":[{"value":"24 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Tina J. Hieken received institutional research funding from Genentech, SkylineDx. Thomas J. Flotte has warrants in Pramana. Jeffrey E. Johnson received institutional research funding from Iovance. Mara A. Piltin received institutional research funding and travel support from Intuitive Surgical and consulting fees from Axogen Inc. James W. Jakub received consultant\/advisory fees from Breath BioMedical, Clarix Imaging. Matthew S. Block received institutional research funding from Alkermes, Bristol-Myers Squibb, Genentech\/Roche, Marker Inc., Merck, nFerence, Perspective Therapeutics, Pharmacyclics, Regeneron, Sorrento, TILT Biotherapeutics, Transgene, and Viewpoint Molecular Targeting. He served in an\u00a0advisory\/consultant role with Perspective Therapeutics, Sorrento Therapeutics, and TILT Biotherapeutics and has patents filed by his employer for \u201cDendritic Cell-Based Vaccines and Uses Thereof,\u201d and \u201cCombinations of Dendritic Cell-Based Vaccines and Checkpoint Inhibitors.\u201d The remaining authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}